Table 2 Previous studies using corneal imaging to describe belamaf-induced and other antibody–drug conjugate-induced ocular toxicity
ADC/disease | Authors | Design (n) | Imaging | Findings and limitations |
|---|---|---|---|---|
Belantamab mafodotin/MM | Farooq et al. [11] | Retrospective review in the patients’ cohort DREAMM-2. (72) | IVCM | Epithelial microcysts and basal opacities |
Largest series, but few IVCM examples | ||||
No quantification | ||||
No space–time kinetics | ||||
Belantamab mafodotin/MM | Matsumyia et al. [17] | Case report (2) | OCT | Hyperreflective lesions in some epithelial areas |
Low-resolution imaging | ||||
Belantamab mafodotin/MM | Rousseau et al. [10] | Image (1) | IVCM | Epithelial microcysts |
No quantification | ||||
No space–time kinetics | ||||
EGFR-inhibitor ABT-414/glioblastoma | Parrozzani et al. [14] | Prospective analysis (10) | IVCM | Epithelial microcysts and subbasal nerve plexus disappearance |
Well detailed but no quantification | ||||
Space–time kinetics done | ||||
Trastuzumab emtansine/breast cancer | Deklerck et al. [15] | Cross-sectional prospective (12) | IVCM | Microcysts mainly in the peripheral epithelium |
No quantification | ||||
Temporal stability of the lesions | ||||
Trastuzumab emtansine/breast cancer | Kreps et al. [16] | Case report (1) | IVCM | No initial images |
Epithelial microcysts and basal deposits | ||||
No quantification | ||||
Stability of the lesions | ||||
Mirvetuximab soravtansine/ovarian, peritoneal, and fallopian tube cancer | Corbelli et al. [18] | Case report (5) | OCT and AS-IR | Subepithelial changes and corneal hyporeflective dots |
Low-resolution imaging | ||||
No spatial quantification | ||||
Space–time kinetics done |